Novo Nordisk A/S’s decision to stop making insulin pens will narrow treatment options for children with diabetes unless non-patented drugmakers such as Biocon Ltd. step in to plug the gap in a $34 ...

Analog insulin will still be available in the pen format under Novo's plan. Back in June, The New York Times reported that South Africa’s public health system had run out of human insulin pens ...

LONDON, Nov 14 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab ... income countries will not suffer from the halting of insulin pen production, because the company is continuing to make ...

In the U.S., Novo Nordisk’s recent decision ... They’re filled in pen devices that are similar to the pens that many insulin products come in. As demand for GLP-1s continues to climb, patients ...

After slashing the U.S. prices of several of its insulin ... pen, will fall from $559 to $140. For Tresiba’s U-100 FlexTouch, the monthly price will be sliced from $508 to $141. “Novo Nordisk ...

Building upon its existing work with IBM Watson Health and Glooko, Novo Nordisk aims to integrate insulin dosing data from connected pen devices with its partners' open ecosystems and diabetes ...

Ellison says the agreement requires Denmark-based manufacturer Novo Nordisk to cap monthly out-of-pocket payments for insulin at $35 a month for the next five years, even for people without health ...

South Africa's competition watchdog probes Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market South Africa’s competition watchdog is investigating ...

Novo Nordisk ... human insulin in vials to South Africa, where more than four million people live with diabetes, but pens are considered much easier to use and more precise. A pen can be set ...